In a cohort of American patients who underwent neoadjuvant platinum-based chemotherapy, Kim et al also observed correlation between SLC31A1 expression in tumor size and tissue platinum concentration, undetectable protein expression and reduced drug load are associated with reduced tumor response and shorter survival time [9, 10]. This evidence concerns the gene SLC31A1 and neoplasm.